DOCSLIB.ORG

Pharmaceutical and Veterinary Compounds and Metabolites

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES High quality reference materials for analytical testing of pharmaceutical and veterinary compounds and metabolites. lgcstandards.com/drehrenstorfer [email protected] LGC Quality | ISO 17034 | ISO/IEC 17025 | ISO 9001 PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES What you need to know Pharmaceutical and veterinary medicines are essential for To facilitate the fair trade of food, and to ensure a consistent human and animal welfare, but their use can leave residues and evidence-based approach to consumer protection across in both the food chain and the environment. In a 2019 survey the globe, the Codex Alimentarius Commission (“Codex”) was of EU member states, the European Food Safety Authority established in 1963. Codex is a joint agency of the FAO (Food (EFSA) found that the number one food safety concern was and Agriculture Office of the United Nations) and the WHO the misuse of antibiotics, hormones and steroids in farm (World Health Organisation). It is responsible for producing animals. This is, in part, related to the issue of growing antibiotic and maintaining the Codex Alimentarius: a compendium of resistance in humans as a result of their potential overuse in standards, guidelines and codes of practice relating to food animals. This level of concern and increasing awareness of safety. The legal framework for the authorisation, distribution the risks associated with veterinary residues entering the food and control of Veterinary Medicinal Products (VMPs) varies chain has led to many regulatory bodies increasing surveillance from country to country, but certain common principles activities for pharmaceutical and veterinary residues in food and apply which are described in the Codex guidelines. water supplies. For example, the EU Directive 96/23/EC sets out the requirements for residue monitoring plans and establishes On the following pages you will the range of substances to be tested in live animals and find our extensive selection of animal products. In addition, each EU member state must have a National Residue Control Plan (NRCP). NRCPs are targeted pharmaceutical and veterinary surveillance testing designed to police the correct use of reference materials, including where veterinary medicinal products. Non-EU countries exporting available the parent compounds, food to the EU must implement monitoring programmes which comply with equivalent food safety levels. associated metabolites and stable isotope labelled (SIL) compounds. In China, the Ministry of Agriculture Announcement No. 235 (中华人民共和国农业部公告第235号) sets out the requirements for residue monitoring plans and establishes the range of Visit lgcstandards.com/ substances to be tested in live animals and animal products. drehrenstorfer to explore the The government also sets National Food Safety Inspections full and extensive range of over (国家食品安全监督抽检) every year to police the correct use of veterinary medicinal products to ensure food safety. In 8,000 Dr. Ehrenstorfer reference addition, a new GB method took effect on 1 April, 2020, entitled materials available for food and ‘National food safety standard - Maximum Residue Limits For environmental analysis. Veterinary Drugs in Food’ (‘食品安全国家标准 动物性食品中兽药 最大残留限量 (报批稿)’). 2 Discover our pharmaceutical and veterinary compounds and metabolites range: lgcstandards.com/drehrenstorfer Our Dr. Ehrenstorfer range of pharmaceutical and veterinary We are continually adding products to this portfolio to maintain reference materials has been designed to support you in your pace with emerging and evolving analytical requirements. Our analytical testing and address different regulatory methods latest and full range can always be explored on our website applied around the world. You will find our comprehensive lgcstandards.com. offering includes both metabolites and stable isotope labelled (SIL) compounds for many of our parent compounds. With all measurements on our certificate of analysis carried out in accordance with ISO 17025 and a majority of products Testing the active drug is often not sufficient, since they are produced under the scope of our ISO 17034 accreditation, metabolized into other biologically active substances. As more we guarantee the highest quality reference materials for your research is conducted in this area, metabolites are increasingly analytical testing. being written into regulations with specific maximum residue limits, necessitating metabolite testing. SIL compounds can be added to samples to negate the ‘matrix effects’ often observed with mass spectrometric techniques such as LC-MSMS, further ensuring the reliability of your analysis. what is your smart solution™ ? Challenge us to meet your analyte needs, no matter the complexity. Put us to the test at lgcstandards.com/custom 3 Discover our pharmaceutical and veterinary compounds and metabolites range: lgcstandards.com/drehrenstorfer pharmaceutical and veterinary compounds and metabolites Dr. Ehrenstorfer has an extensive range of neat, single solution and multicomponent solution products for the analytical testing of pharmaceutical and veterinary compounds and metabolites. In addition, we offer not just the parent compounds, but also stable isotope labelled (SIL) compounds, associated metabolites and SIL variants of metabolites for some products. On the following pages you will find an index of selected parent compounds and available associated SILs and metabolites, allowing you to thoroughly test for pharmaceutical and veterinary compounds. You can also visit lgcstandards.com/drehrenstorfer to browse the full range of products. Product code Description Pack CAS number SIL Metabolite SIL of size Metabolite DRE-C10006000 Aceclofenac 50mg 89796-99-6 NEW DRE-C10008000 Acenocoumarol 10mg 152-72-7 NEW DRE-C10010290 Acepromazine hydrochloride 10mg 973-12-6 DRE-C10010300 Acezpromazine maleate 100mg 3598-37-6 DRE-C10010320 Acepromazine D6 maleate 10mg 1331655-50-5 • DRE-C10011900 4-Acetylaminoantipyrine 100mg 83-15-8 DRE-C10012500 2-Acetamido-5-nitrothiazole 100mg 140-40-9 DRE-C10013700 Acetanilide 100mg 103-84-4 DRE-C10016950 Acetildenafil 10mg 831217-01-7 DRE-C10018700 Acetompenaphthone 100mg 573-20-6 NEW DRE-C10023150 N-Acetyl-L-cysteine 25mg 616-91-1 NEW DRE-C10024000 Acetylsalicylic acid 250mg 50-78-2 DRE-C10024050 Acetylsulfamethoxazole 100mg 21312-10-7 DRE-C10024051 Acetylsulfamethoxazole D4 10mg 1215530-54-3 • DRE-C10024500 N-Acetyl-L-tyrosine 100mg 537-55-3 NEW DRE-C10032000 Acitretin 50mg 55079-83-9 NEW DRE-C10045600 Acyclovir 100mg 59277-89-3 DRE-C10045750 Adapalene 50mg 106685-40-9 NEW DRE-C10045805 Adefovir dipivoxil 100mg 142340-99-6 NEW DRE-C10045810 Adenine 100mg 73-24-5 NEW DRE-C10045820 Adenosine 250mg 58-61-7 DRE-C10045850 Adrenochrome semicarbazone 100mg 69-81-8 DRE-C10046500 Adonit 100mg 488-81-3 DRE-C10047700 Agaric acid 250mg 666-99-9 DRE-C10049000 Aklomide 100mg 3011-89-0 DRE-C10065000 Albendazole 100mg 54965-21-8 DRE-A10065000AL-100 Albendazole 100 µg/mL in Acetonitrile 1ml 54965-21-8 NEW DRE-C10065020 Albendazole-2-amino 100mg 80983-36-4 • DRE-C10065200 Albendazole-2-aminosulfone 50mg 80983-34-2 • DRE-A10065200AL-100 Albendazole-2-aminosulfone 100 µg/mL in 1ml 80983-34-2 • NEW Acetonitrile 4 Discover our pharmaceutical and veterinary compounds and metabolites range: lgcstandards.com/drehrenstorfer Product code Description Pack CAS number SIL Metabolite SIL of size Metabolite DRE-C10065250 Albendazole-2-aminosulfoxide 50mg 80983-35-3 • DRE-C10065300 Albendazole-sulfone 10mg 75184-71-3 • DRE-A10065300AL-100 Albendazole-sulfone 100 µg/mL in Acetonitrile 1ml 75184-71-3 • NEW DRE-C10065400 Albendazole-sulfoxide 10mg 54029-12-8 • DRE-C10065410 Albendazole-sulfoxide D3 (methyl D3) 10mg 1448346-38-0 • DRE-C12772050 Albendazole-2-aminosulfoxide 10mg 936-05-0 • DRE-XA12772050AC Dimetridazole-2-hydroxy 100 µg/mL in Acetone 1.1ml 936-05-0 • DRE-C12772051 Dimetridazole-2-hydroxy D3 10mg 1015855-78-3 • DRE-C10098000 Allantoin 100mg 97-59-6 DRE-C10118000 Allopurinol 100mg 315-30-0 DRE-C15811500 Oxypurinol 10mg 2465-59-0 • NEW DRE-C10142700 Alprostadil 10mg 745-65-3 NEW DRE-C10144000 Altrenogest 100mg 850-52-2 DRE-A10144000AL-100 Altrenogest 100 µg/mL in Acetonitrile 1ml 850-52-2 NEW DRE-C10146000 Amantadine hydrochloride 100mg 665-66-7 DRE-C10148800 Ambroxol hydrochloride 100mg 23828-92-4 DRE-A10148800AL-100 Ambroxol hydrochloride 100 µg/mL in Acetonitrile 1ml 23828-92-4 NEW DRE-C10148850 Amcinonide 100mg 51022-69-6 DRE-CA10158000 Amidate 100mg 17321-47-0 DRE-C10163900 Amikacin 100mg 37517-28-5 NEW DRE-C10166000 4-Aminoantipyrine 10mg 83-07-8 DRE-C10185000 Aminocaproic acid 100mg 60-32-2 NEW DRE-C10202370 2-Aminoflubendazole 10mg 82050-13-3 DRE-L10202370ME 2-Aminoflubendazole 10 µg/mL in Methanol 10ml 82050-13-3 DRE-C10209400 Aminopentamide 10mg 60-46-8 NEW DRE-C10227010 4-Aminosalicylic acid 100mg 65-49-6 DRE-C10227020 5-Aminosalicylic acid 100mg 89-57-6 DRE-C10227200 Aminotadalafil 25mg 385769-84-6 DRE-C10227220 (R,S)-Aminotadalafil 50mg 1093940-68-1 NEW DRE-C10231000 Amitriptyline hydrochloride 100mg 549-18-8 NEW DRE-C10240500 Amlodipine besylate 100mg 111470-99-6 DRE-C10242500 Amoxicillin trihydrate 250mg 61336-70-7 DRE-A10242500AL-100 Amoxicillin trihydrate 100 µg/mL in Acetonitrile 1ml 61336-70-7 NEW DRE-C10243050 Amphotericin B 100mg 1397-89-3 DRE-C10243080 Ampicillin trihydrate 100mg 7177-48-2 DRE-C10243090 Amprenavir 10mg 161814-49-9 NEW DRE-C10243100 Amprolium hydrochloride 250mg 137-88-2 DRE-C10245500 D-Amygdalin 100mg 29883-15-6 DRE-C10246500 Amylmetacresol
Recommended publications
  • Testosterone, Or

    Testosterone, Or

    COSI SIMILI, COSI DIVERSE 1. FOR A FEW ATOMS MORE: TESTOSTERONE AND DOPING A few days ago, the Tour de France winner, Floyd Landis, was found to have a high, indeed impermissible level of testosterone in his urine. Not quite, more of what was actually found in just a while. The sample was taken just after his comeback victory in a critical stage of bicycling’s premier race. If a second sample confirms the problem, Landis’s victory will be disallowed. Testosterone is the principal male sex hormone, produced mainly where… you might suspect from its name. And it is also produced in the ovaries of females. Testosterone is a so-called anabolic steroid, a class of molecules that give us a continuing lesson that almost the same is not the same. All the steroids, the class of molecules that include testosterone, have the same atomic framework – four all-carbon rings, fused together. Three are hexagons, the third ring going off at an angle to the other two. Fused to that last ring is a pentagon of carbon atoms. Call the rings A (6 carbons), B (6), C (6), D (5). Testosterone has an oxygen and a hydrogen (OH) attached to ring D, two CH3 (methyl) groups, one at the juncture of rings C and D, the other at the juncture of A and B. Finally ring A of testosterone has an oxygen attached to it as well, and there is a double bond in that ring. testosterone Testosterone is responsible for the secondary sex changes which occur in male puberty – facial and pubic hair, oiliness of skin, body odor, all that teenage boy stuff.
  • Albany-Molecular-Research-Regulatory

    Albany-Molecular-Research-Regulatory

    PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF A Abiraterone Malta • Benztropine Mesylate Cedarburg • Adenosine Rozzano - Quinto de' Stampi • • * Betaine Citrate Anhydrous Bon Encontre • Betametasone-17,21- Alcaftadine Spain Spain • • Dipropionate Sterile • Alclometasone-17, 21- Spain Betamethasone Acetate Spain Dipropionate • • Altrenogest Spain • • Betamethasone Base Spain Amphetamine Aspartate Rensselaer Betamethasone Benzoate Spain * Monohydrate Milled • Betamethasone Valerate Amphetamine Sulfate Rensselaer Spain * • Acetate Betamethasone-17,21- Argatroban Rozzano - Quinto de' Stampi Spain • • Dipropionate • • • Atenolol India • • Betamethasone-17-Valerate Spain • • Betamethasone-21- Atracurium Besylate Rozzano - Quinto de' Stampi Spain • Phosphate Disodium Salt • • Bromfenac Monosodium Atropine Sulfate Cedarburg Lodi * • Salt Sesquihydrate • • Azanidazole Lodi Bromocriptine Mesylate Rozzano - Quinto de' Stampi • • • • • Azelastine HCl Rozzano - Quinto de' Stampi • • Budesonide Spain • • Aztreonam Rozzano - Valle Ambrosia • • Budesonide Sterile Spain • • B Bamifylline HCl Bon Encontre • Butorphanol Tartrate Cedarburg • Beclomethasone-17, 21- Spain Capecitabine Lodi Dipropionate • C • 2 *Please contact our Accounts Managers in case you are interested in this API. 3 PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF Dexamethasone-17,21- Carbimazole Bon Encontre Spain • Dipropionate
  • Androgenic and Anabolic Activities of Some Newly Synthesized Epiandrosterone and Progesterone Derivatives

    Androgenic and Anabolic Activities of Some Newly Synthesized Epiandrosterone and Progesterone Derivatives

    Scientia Pharmazeutica (Sci. Pharm.) 68, 141-1 57 (2000) O Osterreichische Apotheker-Verlagsgesellschaft m. b. H, Wien, Printed in Austria Androgenic and Anabolic Activities of Some Newly Synthesized Epiandrosterone and Progesterone Derivatives. Y. A. ~aklaai"and M. M. ~osseir'~' Abstract Derivatives of eplandrosterone and progesterone were synthesized. The androgenic and the anabolic activities of some of tlieln were investigated on prepubertal male albino rats of 21 days old by:-i determining tlie weight gain of the body, levator ani muscle, ventral prostate gland, testis, selniilal vesicles, vas deferens and epididymis, ii- esti~natioi~of serum luteinizing (LH) hor~none,iii- liistopatliological examination of the testis and ventral prostate glands. The results from this study showed that the presence of an appended substituted 2- aminopyridine ring at the C- 17 of testosterone gave the maximuin a~idrogenicactivity, whereas the presence of a substituted piperidine ring fused to ring D of 5 a- androstane exhibited tlie maxiini~inanabolic activity. However, filsio~~of a pyrazoline moiety with the ring D of 5 a- androstane led to a compo~undwith considerable androgenic and anabolic act~v~ty. Keywords: epiandrosterone, progesterone, a~idrogenicactivity, anabolic activity, prepubertal rat, inale sex accessory glands, luteinizing horinone, I~istopatl~ology Introduction A~idrogensare a class of steroids responsible for tlie primary and secondary sex characteristics of the male. In addition, these steroids have bee11 found to possess potent anabolic promoting properties. The androgens are formed by the Leydig cells of the testis which is regulated by tlie gonadotropic luteinizing hormone (LH). The latter is secreted by tlie (J - cells of the anterior pitiltary gland under tlie control of the liypotlialainic gonadotropin - releasing l~oni~one.LH polypeptide -cliaiii is bioclie~nically unique and confers the LH biological and il~~~~~l~~~ologicnlspecificity "'".
  • Scopoletin 8-Hydroxylase: a Novel Enzyme Involved in Coumarin

    Scopoletin 8-Hydroxylase: a Novel Enzyme Involved in Coumarin

    bioRxiv preprint doi: https://doi.org/10.1101/197806; this version posted October 4, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Scopoletin 8-hydroxylase: a novel enzyme involved in coumarin biosynthesis and iron- 2 deficiency responses in Arabidopsis 3 4 Running title: At3g12900 encodes a scopoletin 8-hydroxylase 5 6 Joanna Siwinska1, Kinga Wcisla1, Alexandre Olry2,3, Jeremy Grosjean2,3, Alain Hehn2,3, 7 Frederic Bourgaud2,3, Andrew A. Meharg4, Manus Carey4, Ewa Lojkowska1, Anna 8 Ihnatowicz1,* 9 10 1Intercollegiate Faculty of Biotechnology of University of Gdansk and Medical University of 11 Gdansk, Abrahama 58, 80-307 Gdansk, Poland 12 2Université de Lorraine, UMR 1121 Laboratoire Agronomie et Environnement Nancy- 13 Colmar, 2 avenue de la forêt de Haye 54518 Vandœuvre-lès-Nancy, France; 3INRA, UMR 14 1121 Laboratoire Agronomie et Environnement Nancy-Colmar, 2 avenue de la forêt de Haye 15 54518 Vandœuvre-lès-Nancy, France; 16 4Institute for Global Food Security, Queen’s University Belfast, David Keir Building, Malone 17 Road, Belfast, UK; 18 19 [email protected] 20 [email protected] 21 [email protected] 22 [email protected] 23 [email protected] 24 [email protected] 25 [email protected] 26 [email protected] 27 [email protected] 28 *Correspondence: [email protected], +48 58 523 63 30 29 30 The date of submission: 02.10.2017 31 The number of figures: 9 (Fig.
  • Efficiency of Different Methods of Estrus Synchronization Followed by Fixed Time Artificial Insemination in Persian Downy Does

    Efficiency of Different Methods of Estrus Synchronization Followed by Fixed Time Artificial Insemination in Persian Downy Does

    DOI: 10.21451/1984-3143-AR825 Anim. Reprod., v.14, n.2, p.413-417, Apr./Jun. 2017 Efficiency of different methods of estrus synchronization followed by fixed time artificial insemination in Persian downy does Majid Hashemi1, 2, 3, Mazaher Safdarian2 1Razi Vaccine and Serum Research Institute, Shiraz Branch, Agricultural Research, Education and Extension Organization (AREEO), Shiraz, Iran. 2Animal Science Research Department, Fars Agricultural and Natural Resource Research and Education Center, Agricultural Research, Education and Extension Organization (AREEO), Shiraz, Iran. Abstract estrus synchronization can play an important role for managing production system, allowing the density of For evaluating different methods of long term estrous mating and kidding and production of meat and milk synchronization followed by fixed time artificial during specific times of the year for strategic marketing insemination and to select the most efficient method, and other purposes (Baldassarre and Karatzas, 2004, during the breeding season 160 Persian downy does Zhao et al., 2010). In small ruminants, hormonal estrus were equally allocated to groups (n = 20/group). Estrus synchronization is achieved either by reducing the was synchronized using controlled internal drug release length of the luteal phase of the estrous cycle with devices alone (CIDR) or with equine chorionic prostaglandin F2α or by extending the cycle artificially gonadotropin (CIDR-eCG), intravaginal sponge with exogenous progesterone or more potent impregnated with 45 mg fluorgestone acetate alone progestagens (Hashemi et al., 2006, Abecia et al., (Sponge) or with eCG (Sponge-eCG), subcutaneous 2012). Progestogen administration is common and has auricular implant of 2 mg norgestomet alone (Implant) been used with or without accompanying treatments or with eCG (Implant-eCG) or two intramuscular such as gonadatropins or prostaglandin analogs.
  • REVIEW Effects of Androgens on Cardiovascular Remodeling

    REVIEW Effects of Androgens on Cardiovascular Remodeling

    1 REVIEW Effects of androgens on cardiovascular remodeling Yasumasa Ikeda1,2, Ken-ichi Aihara2, Sumiko Yoshida2, Masashi Akaike3 and Toshio Matsumoto2 Departments of 1Pharmacology, 2Medicine and Bioregulatory Sciences and 3Medical Education, The University of Tokushima, Graduate School of Health Biosciences, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan (Correspondence should be addressed to K Aihara; Email: [email protected]) Abstract Androgens, the male sex hormones, exert various biological cardiovascular mortality. However, the influence of androgens effects on many target organs through the transcriptional effects on the cardiovascular system has not been fully elucidated. of the nuclear androgen receptor (AR). ARs are expressed not Toclarify this issue, we analyzed the effects of administration of only in classical target organs, such as the brain, genital organs, angiotensin II and doxorubicin, an anticancer agent, in a bone, and skeletal muscles, but also in the cardiovascular loading model in male wild-type and AR-deficient mice. In system. Because the female sex hormones estrogens are well- this review, we focus on the actions of androgens as potential known to protect against cardiovascular disease, sex has targets for the prevention of cardiovascular diseases in males. been considered to have a significant clinical impact on Journal of Endocrinology (2012) 214, 1–10 Introduction In addition, previous studies have shown that testosterone replacement tends to increase cardiovascular risk among Cardiovascular disease remains a major cause of death in both men of all ages (Calof et al. 2005, Haddad et al. 2007, womenandmenworldwideandappearstoincrease Fernandez-Balsells et al. 2010). On the other hand, recent morbidity and mortality in industrial countries.
  • Morning Glory Systemically Accumulates Scopoletin And

    Morning Glory Systemically Accumulates Scopoletin And

    Morning Glory Systemically Accumulates Scopoletin and Scopolin after Interaction with Fusarium oxysporum Bun-ichi Shimizua,b,*, Hisashi Miyagawaa, Tamio Uenoa, Kanzo Sakatab, Ken Watanabec, and Kei Ogawad a Graduate School of Agriculture, Kyoto University, Kyoto 606Ð8502, Japan b Institute for Chemical Research, Kyoto University, Uji 611-0011, Japan. Fax: +81-774-38-3229. E-mail: [email protected] c Ibaraki Agricultural Center, Ibaraki 311Ð4203, Japan d Kyushu National Agricultural Experiment Station, Kumamoto 861Ð1192, Japan * Author for correspondence and reprint requests Z. Naturforsch. 60c,83Ð90 (2005); received September 14/October 29, 2004 An isolate of non-pathogenic Fusarium, Fusarium oxysporum 101-2 (NPF), induces resis- tance in the cuttings of morning glory against Fusarium wilt caused by F. oxysporum f. sp. batatas O-17 (PF). The effect of NPF on phenylpropanoid metabolism in morning glory cuttings was studied. It was found that morning glory tissues responded to treatment with NPF bud-cell suspension (108 bud-cells/ml) with the activation of phenylalanine ammonia- lyase (PAL). PAL activity was induced faster and greater in the NPF-treated cuttings com- pared to cuttings of a distilled water control. High performance liquid chromatography analy- sis of the extract from tissues of morning glory cuttings after NPF treatment showed a quicker induction of scopoletin and scopolin synthesis than that seen in the control cuttings. PF also the induced synthesis of these compounds at 105 bud-cells/ml, but inhibited it at 108 bud- cells/ml. Possibly PF produced constituent(s) that elicited the inhibitory effect on induction of the resistance reaction.
  • Criteria to Indicate Testosterone Administration

    Criteria to Indicate Testosterone Administration

    Br. J. Sp. Med; Vol 24, No. 4 Br J Sports Med: first published as 10.1136/bjsm.24.4.253 on 1 December 1990. Downloaded from Criteria to indicate testosterone administration A.T. Kicman1, R.V. Brooks2, S.C. Collyere, D.A. Cowan', M.N. Nanjee2, G.J. Southan2 and M.J. Wheelee 'Drug Control and Teaching Centre, King's College, London University 2Department of Chemical Pathology, UMDS, London University A detection method for testosterone administration was was found to increase after an intramuscular injection developed using radioimmunoassay to measure the of testosterone heptanoate in all ten normal males, urinary ratios of testosterone (T) to epitestosterone (E) and although there was an overlap between the basal to luteinizing hormone (LH). A comparative study of the range and that obtained three days after injection. effect on these ratios of a single intramuscular injection of testosterone heptanoate followed by stimulation with The method used was radioimmunoassay as protein human chorionic gonadotrophin (HCG) in three normal hormones cannot be measured by gas liquid chroma- men was undertaken. To allow immediate investigation, a tography-mass spectrometry (GLC-MS). commercially supplied epitestosterone antiserum was In 1983, the International Olympic Committee used. This study showed that both T/E and T/LH ratios (IOC) adopted the ratio of urinary testosterone to could be used to detect testosterone administration, the epitestosterone (T/E) as the sole test for testosterone latter also being an indicator of HCG use due to doping as both these hormones could be convenient- cross-reactivity with the LH antiserum. Subsequently, an ly measured by GLC-MS.
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • 169 2016 Interim Meeting Science and Public Health - 1

    169 2016 Interim Meeting Science and Public Health - 1

    169 2016 Interim Meeting Science and Public Health - 1 REPORTS OF THE COUNCIL ON SCIENCE AND PUBLIC HEALTH The following reports, 1–4, were presented by S. Bobby Mukkamala, MD, Chair: 1. URINE DRUG TESTING Reference committee hearing: see report of Reference Committee K. HOUSE ACTION: RECOMMENDATIONS ADOPTED AS FOLLOWS REMAINDER OF REPORT FILED See Policies H-95.985 and D-120.936 INTRODUCTION Over the past two decades, the rate of opioid prescribing, especially for patients with chronic non-cancer pain, has increased dramatically. It is estimated that between 9.6 and 11.5 million Americans are currently being prescribed long-term opioid therapy.1 The overall increase in prescribing has been associated with a parallel increase in unintentional overdoses and deaths from prescription opioids.2 In 2014, a total of 47,055 drug overdose deaths occurred in the United States; 61% of these involved some type of opioid, including heroin. Overdose deaths from heroin have quadrupled in recent years, and the majority of past year users of heroin report they used opioids in a nonmedical fashion prior to heroin initiation; hence, the availability of pharmaceutical opioids is relevant to the national heroin use and overdose death epidemics. In the most recent available report, benzodiazepines were involved in 31% of the opioid-related overdoses.3 Despite clinical recommendations to the contrary, the rate of opioid and benzodiazepine co-prescribing also continues to rise.3-5 Identifying patients at risk for drug misuse is a challenge. There is no definitive way for physicians to predict which of their patients will develop misuse problems with controlled substances.
  • Etats Rapides

    Etats Rapides

    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr

    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr

    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine